Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.
Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser
Thomas B. Cueni, Thomas B. Cueni
Since the world’s response to COVID-19 began, we have all worked to outrun a virus that has so far proven faster than we have been. Industry, governments, hospitals, providers, suppliers, researchers indeed entire countries found themselves on their heels for much of 2020. The significant efforts and associated learnings accumulated since early 2020 enable meaningful early insights to inform the current crisis and the future course. Swift pathogen surveillance and sharing, an enabling innovation ecosystem built on strong intellectual property protections, global voluntary partnerships supporting an unprecedented manufacturing of COVID-19 vaccines and treatments, are part of the lessons learned. It is also clear however that collective efforts are needed to achieve health equity, while ensuring health systems and delivery infrastructure are strengthened. The biopharmaceutical industry, having played a critical role in the response against COVID-19, is committed to working with stakeholders and is contributing game changing solutions to equitable access to ensure vulnerable populations are prioritized.